{"id":12227,"date":"2003-11-01T16:17:22","date_gmt":"2003-11-01T16:17:22","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=12227"},"modified":"2014-05-27T10:40:31","modified_gmt":"2014-05-27T10:40:31","slug":"volume-4-number-9-november-2003-2","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/12227","title":{"rendered":"Volume 4 Number 9 November 2003"},"content":{"rendered":"<p><strong>This is the third consecutive issue of HTB to lead with an FDA or EMEA drug warning letter.<\/strong><\/p>\n<p>The issue this month is that the triple-nucleoside combination of ddI\/3TC\/tenofovir failed to produce a viral load reduction &gt;2logs by week 12 in a group of treatment na\u00efve patients. It did however provide nearly all of them with their first set of drug-resistant mutations. It should be noted that the European version of this issue letter from Gilead also cautions against using ddI\/3TC\/tenofovir in treatment experienced patients.<\/p>\n<p>Fortunately, this combination is unlikely to be currently widely used in the UK, and the caution against triple-nucleoside combinations in the 2003 BHIVA guidelines should limit any further prescribing of any triple-nucleoside combination in first-line therapy.<\/p>\n<p>A further report of yet another poorly performing triple-nucleoside combination &#8211; this time with abacavir\/ddI\/d4T &#8211; is included.<\/p>\n<p>The November HTB issue also includes a report on strategic treatment interruptions studies in resource-limited settings from the 13th International Conference on AIDS and STIs in Africa (ICASA).<\/p>\n<p>STIs have now been well studied in countries which have widespread access to ARV therapy, and results from recent studies are reported on.<\/p>\n<p>These finding have not been particularly encouraging and the risk from resistance when stopping and restarting NNRTI-based regimes will apply wherever these studies are being run.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This is the third consecutive issue of HTB to lead with an FDA or EMEA drug warning letter. The issue this month is that the triple-nucleoside combination of ddI\/3TC\/tenofovir failed to produce a viral load reduction &gt;2logs by week 12 &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-12227","post","type-post","status-publish","format-standard","hentry","category-editorial"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=12227"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12227\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=12227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=12227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=12227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}